{"id":745134,"date":"2015-08-18T07:00:00","date_gmt":"2015-08-18T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\/"},"modified":"2025-11-07T01:25:01","modified_gmt":"2025-11-07T06:25:01","slug":"fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\/","title":{"rendered":"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review"},"content":{"rendered":"<p class=\"bwalignc\">       Merck Provides Additional Update: FDA Extends Action        Date for Additional sBLA in Ipilimumab-Refractory Advanced Melanoma     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the U.S. Food and Drug Administration (FDA) has accepted<br \/>\n      for review a supplemental Biologics License Application (sBLA) for<br \/>\n      KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), Merck\u2019s anti-PD-1 therapy. Merck<br \/>\n      is seeking approval for KEYTRUDA, at the currently approved dose of 2<br \/>\n      mg\/kg every three weeks, for the first-line treatment of unresectable or<br \/>\n      metastatic melanoma patients. The FDA granted Priority Review with a<br \/>\n      PDUFA, or target action, date of December 19, 2015. Additionally, the<br \/>\n      FDA has extended the action date for a separate sBLA for KEYTRUDA for<br \/>\n      the treatment of patients with ipilimumab-refractory advanced melanoma.<br \/>\n      The new action date is now December 24, 2015.\n    <\/p>\n<p>\n      \u201cThrough our clinical program for KEYTRUDA we have accumulated<br \/>\n      substantial data on the role of our anti-PD-1 therapy in advanced<br \/>\n      melanoma. We look forward to the FDA&#8217;s review of each of these<br \/>\n      applications, and to delivering on our goal of helping patients with<br \/>\n      advanced melanoma to achieve long-term disease control and survival,\u201d<br \/>\n      said Dr. Roger M. Perlmutter, president, Merck Research Laboratories.\n    <\/p>\n<p>\n      KEYTRUDA is currently indicated in the United States at a dose of 2<br \/>\n      mg\/kg administered as an intravenous infusion over 30 minutes every<br \/>\n      three weeks for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma and disease progression following ipilimumab and, if<br \/>\n      BRAF V600 mutation positive, a BRAF inhibitor. This indication is<br \/>\n      approved under accelerated approval based on tumor response rate and<br \/>\n      durability of response. An improvement in survival or disease-related<br \/>\n      symptoms has not yet been established. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      The sBLA submission for first-line use in advanced melanoma was based in<br \/>\n      part on data from KEYNOTE-006, a Phase 3 study which evaluated KEYTRUDA<br \/>\n      in 834 patients with unresectable or metastatic melanoma with<br \/>\n      progression of disease. Findings from this study were presented at the<br \/>\n      2015 American Associated for Cancer Research (AACR) Annual Meeting and<br \/>\n      published in the <i>New England Journal of Medicine<\/i><sup><i>i<\/i><\/sup>.\n    <\/p>\n<p>\n      <b>Update on sBLA in Ipilimumab-Refractory Advanced Melanoma<\/b>\n    <\/p>\n<p>\n      The sBLA for ipilimumab-refractory advanced melanoma included data from<br \/>\n      KEYNOTE-002. KEYNOTE-002 is the Phase 2 study which demonstrated<br \/>\n      KEYTRUDA was superior to chemotherapy in helping more patients with<br \/>\n      ipilimumab-refractory advanced melanoma achieve progression-free<br \/>\n      survival (PFS). In an effort to provide the FDA with the most robust<br \/>\n      data for KEYTRUDA in this population, Merck submitted an additional<br \/>\n      analysis from KEYNOTE-002. The submission constitutes a major amendment<br \/>\n      which will require additional time for review.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae <\/b><\/sup><b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks<br \/>\n      the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By<br \/>\n      binding to the PD-1 receptor and blocking the interaction with the<br \/>\n      receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition<br \/>\n      of the immune response, including the anti-tumor immune response.\n    <\/p>\n<p>\n      Merck is advancing a broad and fast-growing clinical development program<br \/>\n      for KEYTRUDA with more than 100 clinical trials \u2013 across more than 30<br \/>\n      tumor types and enrolling more than 16,000 patients \u2013 both as a<br \/>\n      monotherapy and in combination with other therapies.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients, including Grade 2 or<br \/>\n      3 cases in 8 (1.9%) and 1 (0.2%) patients, respectively. Monitor<br \/>\n      patients for signs and symptoms of pneumonitis. Evaluate suspected<br \/>\n      pneumonitis with radiographic imaging. Administer corticosteroids for<br \/>\n      Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2;<br \/>\n      permanently discontinue KEYTRUDA for Grade 3 or 4 pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients<br \/>\n      respectively, receiving KEYTRUDA (pembrolizumab). Monitor patients for<br \/>\n      signs and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor for signs and symptoms of hypophysitis (including<br \/>\n      hypopituitarism and adrenal insufficiency). Administer corticosteroids<br \/>\n      for Grade 2 or greater hypophysitis. Withhold KEYTRUDA for Grade 2;<br \/>\n      withhold or discontinue for Grade 3; and permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, has occurred<br \/>\n      in patients receiving KEYTRUDA. Monitor patients for hyperglycemia and<br \/>\n      other signs and symptoms of diabetes. Administer insulin for type 1<br \/>\n      diabetes, and withhold KEYTRUDA in cases of severe hyperglycemia until<br \/>\n      metabolic control is achieved.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting<br \/>\n      of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of<br \/>\n      interstitial nephritis with renal failure (0.5%), one Grade 3 and one<br \/>\n      Grade 4. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA<br \/>\n      (pembrolizumab) for Grade 2; permanently discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in patients treated with KEYTRUDA (pembrolizumab): exfoliative<br \/>\n      dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic<br \/>\n      anemia, partial seizures arising in a patient with inflammatory foci in<br \/>\n      brain parenchyma, severe dermatitis including bullous pemphigoid,<br \/>\n      myasthenic syndrome, optic neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Infusion-related reactions, including severe and life-threatening<br \/>\n      reactions, have occurred in patients receiving KEYTRUDA. Monitor<br \/>\n      patients for signs and symptoms of infusion-related reactions including<br \/>\n      rigors, chills, wheezing, pruritus, flushing, rash, hypotension,<br \/>\n      hypoxemia, and fever. For severe or life-threatening reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      For the treatment of advanced melanoma, KEYTRUDA was discontinued for<br \/>\n      adverse reactions in 9% of 411 patients across all doses studied.<br \/>\n      Adverse reactions, reported in at least two patients, that led to<br \/>\n      discontinuations of KEYTRUDA were: pneumonitis, renal failure, and pain.<br \/>\n      Serious adverse reactions occurred in 36% of patients receiving<br \/>\n      KEYTRUDA. The most frequent serious adverse drug reactions reported in<br \/>\n      2% or more of patients were renal failure, dyspnea, pneumonia, and<br \/>\n      cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%),<br \/>\n      decreased appetite (26%), constipation (21%), arthralgia (20%), and<br \/>\n      diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA (pembrolizumab).<br \/>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA<br \/>\n      have not been established in pediatric patients.\n    <\/p>\n<p>\n      <b>About Melanoma<\/b>\n    <\/p>\n<p>\n      Melanoma, the most serious form of skin cancer, is characterized by the<br \/>\n      uncontrolled growth of pigment-producing cells. The incidence of<br \/>\n      melanoma has been increasing over the past four decades \u2013 approximately<br \/>\n      232,000 new cases were diagnosed worldwide in 2012. In the U.S.,<br \/>\n      melanoma is one of the most common types of cancer diagnosed and is<br \/>\n      responsible for the vast majority of skin cancer deaths. In 2015, an<br \/>\n      estimated 73,870 people are expected to be diagnosed and an estimated<br \/>\n      9,940 people are expected to die of the disease in the U.S. alone. The<br \/>\n      five-year survival rates for advanced or metastatic melanoma (Stage IV)<br \/>\n      are estimated to be 15 to 20 percent.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey&nbsp;\u2013&nbsp;from lab to clinic&nbsp;\u2013&nbsp;to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51164422&amp;newsitemid=20150818005715&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=e9783bd2136d39e2715cd9c25ebf9855\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51164422&amp;newsitemid=20150818005715&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=dd1222c973d6b27c7265b419d41be2d8\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51164422&amp;newsitemid=20150818005715&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=b89869c89ddabd5fe5418110b1c4670a\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=51164422&amp;newsitemid=20150818005715&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=a4e7c44ffe3d149847454a810fde9495\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2Fmerck&amp;esheet=51164422&amp;newsitemid=20150818005715&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=7f995c7ac92bb2956a0988802c4628aa\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful.&nbsp;If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51164422&amp;newsitemid=20150818005715&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=1254df1eb1eda667fd8e34a0eab1bada\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51164422&amp;newsitemid=20150818005715&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=7&amp;md5=e4d06446033903a21cc02b6ad783684e\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51164422&amp;newsitemid=20150818005715&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=8&amp;md5=23c2240353c548d4f4732dbf51c027d8\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a>\n    <\/p>\n<p>\n      _______________________________________\n    <\/p>\n<p>\n      <sup><i><b>i<\/b><\/i><\/sup> <b>Robert C, et al. Pembrolizumab versus<br \/>\n      Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521-2532<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150818005715r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Investors:<br \/>Justin        Holko, 908-740-1879<br \/>An Phan, 908-255-6325     <\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA \u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy. Merck is seeking approval for KEYTRUDA, at the currently approved dose of 2 mg\/kg every three weeks, for the first-line treatment of unresectable or metastatic melanoma patients. The FDA granted Priority Review with a PDUFA, or target action, date of December 19, 2015. Additionally, the FDA has extended the action date for a separate sBLA for KEYTRUDA for the treatment of patients with ipilimumab-refractory advanced melanoma. The new action date is now December 24, 2015. \u201cThrough our clinical program for KEYTRUDA we have accumulated substantial data on the role of our anti-PD-1 therapy in advanced melanoma. We look forward to the FDA&#8217;s review of each of these applications, and to delivering on our goal of helping patients<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745134","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA \u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy. Merck is seeking approval for KEYTRUDA, at the currently approved dose of 2 mg\/kg every three weeks, for the first-line treatment of unresectable or metastatic melanoma patients. The FDA granted Priority Review with a PDUFA, or target action, date of December 19, 2015. Additionally, the FDA has extended the action date for a separate sBLA for KEYTRUDA for the treatment of patients with ipilimumab-refractory advanced melanoma. The new action date is now December 24, 2015. \u201cThrough our clinical program for KEYTRUDA we have accumulated substantial data on the role of our anti-PD-1 therapy in advanced melanoma. We look forward to the FDA&#039;s review of each of these applications, and to delivering on our goal of helping patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\\\/\",\"name\":\"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-08-18T07:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\/","og_locale":"en_US","og_type":"article","og_title":"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA \u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy. Merck is seeking approval for KEYTRUDA, at the currently approved dose of 2 mg\/kg every three weeks, for the first-line treatment of unresectable or metastatic melanoma patients. The FDA granted Priority Review with a PDUFA, or target action, date of December 19, 2015. Additionally, the FDA has extended the action date for a separate sBLA for KEYTRUDA for the treatment of patients with ipilimumab-refractory advanced melanoma. The new action date is now December 24, 2015. \u201cThrough our clinical program for KEYTRUDA we have accumulated substantial data on the role of our anti-PD-1 therapy in advanced melanoma. We look forward to the FDA's review of each of these applications, and to delivering on our goal of helping patients","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:01+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\/","name":"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-08-18T07:00:00+00:00","dateModified":"2025-11-07T06:25:01+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"8393478b-1496-454b-be59-8cc7857e5675","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/FDA-Accepts-Supplemental-Biologics-License-Application-sBLA-for-KEYTRUDA-pembrolizumab-Mercks-Anti-PD-1-Therapy-for-First-Line-Treatm-XRQMO.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745134\/revisions"}],"predecessor-version":[{"id":3674611,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745134\/revisions\/3674611"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745134"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}